Your browser is no longer supported. Please, upgrade your browser.
Settings
LLY Eli Lilly and Company daily Stock Chart
LLY [NYSE]
Eli Lilly and Company
IndexS&P 500 P/E30.86 EPS (ttm)2.89 Insider Own11.30% Shs Outstand1.06B Perf Week1.37%
Market Cap94.36B Forward P/E16.07 EPS next Y5.54 Insider Trans-1.19% Shs Float1.06B Perf Month3.15%
Income3.04B PEG2.68 EPS next Q1.28 Inst Own78.60% Short Float1.08% Perf Quarter11.17%
Sales23.34B P/S4.04 EPS this Y-37.00% Inst Trans-0.03% Short Ratio3.09 Perf Half Y2.40%
Book/sh13.86 P/B6.43 EPS next Y7.65% ROA2.60% Target Price91.94 Perf Year5.60%
Cash/sh4.52 P/C19.70 EPS next 5Y11.52% ROE8.20% 52W Range73.69 - 89.87 Perf YTD5.46%
Dividend2.25 P/FCF40.40 EPS past 5Y-15.00% ROI6.60% 52W High-0.33% Beta0.20
Dividend %2.53% Quick Ratio1.00 Sales past 5Y0.20% Gross Margin73.00% 52W Low21.55% ATR1.08
Employees40655 Current Ratio1.40 Sales Q/Q9.00% Oper. Margin14.90% RSI (14)71.36 Volatility1.10% 1.20%
OptionableYes Debt/Eq0.81 EPS Q/Q- Profit Margin4.80% Rel Volume0.59 Prev Close89.07
ShortableYes LT Debt/Eq0.65 EarningsJul 24 BMO Payout200.80% Avg Volume3.72M Price89.57
Recom2.30 SMA203.25% SMA505.87% SMA2008.07% Volume2,174,661 Change0.56%
Jun-08-18Initiated Cantor Fitzgerald Overweight $100
Apr-13-18Upgrade BMO Capital Markets Underperform → Market Perform $74 → $79
Jan-22-18Downgrade Credit Suisse Neutral → Underperform
Jan-16-18Downgrade Goldman Buy → Neutral
Jan-05-18Upgrade Argus Hold → Buy
Oct-10-17Downgrade Credit Suisse Outperform → Neutral
Jul-26-17Downgrade Leerink Partners Outperform → Mkt Perform
Apr-27-17Downgrade Argus Buy → Hold
Apr-17-17Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-07-17Reiterated Barclays Overweight $85 → $90
Mar-20-17Reiterated UBS Neutral $70 → $85
Dec-16-16Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-27-16Upgrade Goldman Neutral → Buy
Sep-08-16Upgrade JP Morgan Neutral → Overweight
May-02-16Reiterated Leerink Partners Outperform $96 → $101
Apr-06-16Initiated Societe Generale Hold $78
Dec-28-15Reiterated Leerink Partners Outperform $93 → $95
Dec-07-15Upgrade Deutsche Bank Hold → Buy $85 → $99
Dec-01-15Upgrade Barclays Equal Weight → Overweight $75 → $95
Nov-12-15Reiterated Leerink Partners Outperform $90 → $93
Jul-16-18 10:45AM  J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay Zacks
07:55AM  The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon Zacks
Jul-15-18 03:05PM  3 Dividend Stocks That Should Pay You the Rest of Your Life Motley Fool
Jul-13-18 02:45PM  Here are Q2's 10 biggest VC-backed exits from the Bay Area American City Business Journals
10:54AM  Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom Zacks
08:17AM  Better Buy: Acadia Pharmaceuticals vs. Eli Lilly Motley Fool
Jul-12-18 06:45AM  New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability PR Newswire
Jul-11-18 09:21AM  The Sad Truth: This Biotech Investing Strategy Almost Always Works Motley Fool
07:30AM  [$$] Big Stock Buys in IBM, Lilly by Norway's Biggest Bank Barrons.com
Jul-10-18 11:54AM  Trump Tweets Threat to Pfizer but Investors Shrug it Off InvestorPlace
09:15AM  Biogen Is the Right Alzheimers Stock At the Wrong Time InvestorPlace
Jul-09-18 09:09AM  Better Buy: Eli Lilly and Company vs. AbbVie Motley Fool
Jul-06-18 05:06PM  Alzheimer's Research Gets Glimmer of Hope, Not for First Time Bloomberg
12:59PM  Top Stocks Set to Disrupt the Diabetes Market Motley Fool
09:35AM  Biogen's Alzheimer Disease Candidate Succeeds in Phase II Zacks
Jul-05-18 11:46AM  Go Long Pfizer Stock Its an Easy Pill to Swallow InvestorPlace
Jul-02-18 07:30AM  Blog Exposure - Eli Lilly's Taltz(R) Meets Primary Endpoint in Phase-3 Study for Treatment of Ankylosing Spondylitis ACCESSWIRE
Jun-29-18 11:36AM  Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study Zacks
06:45AM  Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine PR Newswire
Jun-28-18 04:30PM  Lilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement PR Newswire
08:38AM  The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern Zacks
08:26AM  Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut Benzinga
06:45AM  Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients PR Newswire
Jun-27-18 04:32PM  AHS 2018: Lilly's Emgality (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA) PR Newswire
04:27PM  AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache PR Newswire
11:15AM  Top Research Reports for Amazon, Intel & Eli Lilly Zacks
Jun-26-18 11:09AM  Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies Zacks
09:31AM  Is Pfizer's Lead Growth Driver in Trouble? Motley Fool
Jun-25-18 11:23AM  Lilly Wins Favorable Ruling From U.S. Court in Alimta Row Zacks
08:39AM  Lilly's Jardiance meets main goal of two diabetes trials Reuters
08:00AM  First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes PR Newswire
08:00AM  Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes PR Newswire
06:45AM  Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache PR Newswire
Jun-24-18 09:25AM  Eli Lilly and Company (NYSE:LLY) Is Trading At A 23.26% Discount Simply Wall St.
09:00AM  Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW PR Newswire
06:31AM  5 Biggest Blockbuster Diabetes Drugs of the Future Motley Fool
Jun-23-18 10:00AM  Novo reveals more Ozempic data on change in body weight by baseline BMI Reuters
10:00AM  New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes PR Newswire
10:00AM  Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors PR Newswire
08:00AM  Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes PR Newswire
Jun-22-18 08:02PM  Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma TheStreet.com
04:27PM  U.S. District Court rules in favor of Lilly's Alimta patent Reuters
03:49PM  U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit PR Newswire
08:31AM  Lilly Completes Acquisition of ARMO BioSciences PR Newswire
Jun-21-18 03:39PM  Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study Zacks
07:28AM  Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities ACCESSWIRE
Jun-20-18 09:30AM  LLY vs. NVO: Which Stock Should Value Investors Buy Now? Zacks
09:02AM  NYSE Pharma And Biotech Dividend Stock Picks Simply Wall St.
Jun-19-18 09:30AM  Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year? Zacks
08:55AM  Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis Zacks
Jun-18-18 04:27PM  Lilly Declares Third-Quarter 2018 Dividend PR Newswire
07:42AM  Large Cap Pharma Stock Outlook: Short-Term Struggle Likely Zacks
Jun-17-18 10:06AM  Better Buy: Johnson & Johnson vs. Eli Lilly Motley Fool
Jun-15-18 05:01PM  Teva Scraps A Study In Cluster Headaches And This Rival Benefits Investor's Business Daily
09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
Jun-14-18 05:48PM  Eli Lilly CEO: 'It's time for a change' in the drug pricing system CNBC
05:09PM  Should You Be Tempted To Sell Eli Lilly and Company (NYSE:LLY) Because Of Its PE Ratio? Simply Wall St.
02:43PM  Eli Lilly CEO: 'It's time for a change' in the drug prici... CNBC Videos
Jun-13-18 03:51PM  Lilly's lupus treatment succeeds in mid-stage trial Reuters
01:44PM  Lilly's lupus treatment succeeds in mid-stage trial Reuters
10:41AM  J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit Zacks
Jun-12-18 10:56PM  [$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimers Drug Trials The Wall Street Journal
07:17PM  [$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials The Wall Street Journal
04:47PM  Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test TheStreet.com
04:17PM  AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap Investor's Business Daily
02:06PM  AstraZeneca, Lilly halt tests of experimental Alzheimer's treatment American City Business Journals
01:21PM  Eli Lilly, Electronic Arts, PayPal, Palo Alto Networks & ... CNBC Videos
10:24AM  Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate Zacks
09:25AM  Alzheimer's Research Stumbles Again: What's the Road Ahead? Zacks
08:35AM  Lilly-AstraZeneca latest to abandon Alzheimer's drug trials Reuters
02:49AM  Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests Bloomberg
02:00AM  Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease PR Newswire
12:40AM  [$$] AstraZeneca and Eli Lilly scrap Alzheimers drug trial Financial Times
Jun-11-18 07:04PM  Cramer Remix: What Trumps endgame with China could reall... CNBC Videos
07:01PM  Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't TheStreet.com
07:01PM  Cramer Remix: What Trumps endgame with China could really be about CNBC
06:39PM  Cramer: Eli Lilly's share price recovery symbolizes this ... CNBC Videos
06:29PM  Market attitude seen in Eli Lilly's share price recovery CNBC Videos
06:12PM  Cramer: Eli Lilly's share price recovery symbolizes this market's attitude CNBC
10:57AM  AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer Zacks
10:00AM  Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval Zacks
09:37AM  JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space Zacks
09:08AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie Zacks
07:00AM  Elanco Animal Health Introduces New Respiratory PRRS Vaccine PR Newswire
06:45AM  Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology PR Newswire
Jun-08-18 08:00PM  [$$] How Robots Are Making Better Drugs, Faster The Wall Street Journal
10:27AM  Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks
07:44AM  Stocks making the biggest moves premarket: VZ, AAPL, SFIX, PM, FB & more CNBC
Jun-07-18 04:24PM  Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care Benzinga
10:11AM  J&J Receives Buyout Offer for Sterilization Products Unit Zacks
Jun-06-18 11:20AM  [$$] How Robots Are Making Better Drugs, Faster The Wall Street Journal
Jun-05-18 02:53PM  Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp. PR Newswire
10:15AM  DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial PR Newswire
06:45AM  FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression PR Newswire
Jun-04-18 11:05AM  Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis Zacks
Jun-01-18 01:58PM  Lilly gets U.S. nod for arthritis drug, sets price well below rivals Reuters
12:04PM  FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis PR Newswire
06:45AM  Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis PR Newswire
May-31-18 05:00PM  Lilly to Participate in Goldman Sachs Global Healthcare Conference PR Newswire
10:58AM  Top Diabetes Stocks to Buy Today Motley Fool
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LILLY ENDOWMENT INC10% OwnerJul 06Sale87.44180,00015,738,300121,700,804Jul 09 10:45 AM
Pusey Leigh AnnSVP, Corp. Affairs & Comm.Jul 05Option Exercise0.002,39402,394Jul 09 11:58 AM
LILLY ENDOWMENT INC10% OwnerJul 05Sale86.62170,00014,725,740121,880,804Jul 06 11:13 AM
LILLY ENDOWMENT INC10% OwnerJun 15Sale86.65180,00015,597,720122,050,804Jun 18 12:39 PM
Skovronsky DanielSVP, CSO, and Pres. LRLJun 14Buy86.2210,000862,20055,199Jun 14 04:08 PM
LILLY ENDOWMENT INC10% OwnerJun 14Sale86.31107,6989,295,414122,230,804Jun 15 11:00 AM
LILLY ENDOWMENT INC10% OwnerJun 13Sale86.2711,104957,953122,338,502Jun 14 11:58 AM
LILLY ENDOWMENT INC10% OwnerJun 11Sale86.3851,1984,422,637122,349,606Jun 12 02:46 PM
LILLY ENDOWMENT INC10% OwnerJun 04Sale85.13135,47811,532,565122,400,804Jun 05 11:20 AM
LILLY ENDOWMENT INC10% OwnerJun 01Sale85.3139,5223,371,661122,536,282Jun 04 02:25 PM
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSAMay 31Sale85.0025,0002,125,000124,534Jun 01 04:22 PM
LILLY ENDOWMENT INC10% OwnerMay 30Sale83.85180,00015,092,640122,575,804May 31 01:18 PM
Shaw ChristiSVP and Pres., Lilly Bio-MedsMay 29Sale82.108,426691,7750May 31 01:05 PM
LILLY ENDOWMENT INC10% OwnerMay 11Sale81.97140,00011,475,940122,755,804May 14 02:29 PM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthMay 03Sale78.509,027708,620135,458May 03 04:34 PM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthMay 01Option Exercise0.0020,0000153,201May 03 04:34 PM
Shaw ChristiSVP and Pres., Lilly Bio-MedsMay 01Option Exercise0.0013,750013,750May 03 04:29 PM
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSAMay 01Option Exercise0.0020,0000158,468May 03 04:26 PM
LILLY ENDOWMENT INC10% OwnerApr 25Sale80.85180,00014,553,614122,895,804Apr 26 12:38 PM
Mahony SusanSVP & Pres., Lilly OncologyApr 16Sale80.0817,3791,391,71028,273Apr 17 03:29 PM
Mahony SusanSVP & Pres., Lilly OncologyApr 13Sale80.145,165413,92345,652Apr 17 03:29 PM
Smiley Joshua LSVP and CFOMar 16Sale79.203,000237,60020,029Mar 20 12:06 PM
Zakrowski Donald AChief Accounting OfficerMar 01Sale76.5086065,7901,637Mar 05 03:30 PM
Zakrowski Donald AChief Accounting OfficerFeb 21Sale77.5587667,9342,472Feb 23 05:42 PM
Norton JohnaSenior VP, Global QualityFeb 16Option Exercise0.0048048Feb 21 10:28 AM
Zakrowski Donald AChief Accounting OfficerFeb 05Sale81.0990072,9814,130Feb 05 06:39 PM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthFeb 05Sale81.129,625780,780133,201Feb 05 06:37 PM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthFeb 01Option Exercise0.0021,3260152,120Feb 05 06:37 PM
Zulueta Alfonso GSVP & President, Lilly Int'lFeb 01Option Exercise0.0015,993065,357Feb 05 06:33 PM
Ricks David APresident & CEOFeb 01Option Exercise0.0021,3260140,809Feb 05 06:31 PM
Mahony SusanSVP & Pres., Lilly OncologyFeb 01Option Exercise0.0021,326060,350Feb 05 06:24 PM
Lundberg Jan MEVP,Science&Tech and Pres. LRLFeb 01Option Exercise0.0036,2520214,295Feb 05 06:21 PM
Harrington Michael JSenior VP and General CounselFeb 01Option Exercise0.0024,5240102,738Feb 05 06:19 PM
Fry Stephen FSVP, HR & DiversityFeb 01Option Exercise0.0017,0600107,820Feb 05 06:15 PM
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSAFeb 01Option Exercise0.0021,3260147,980Feb 05 06:12 PM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMFeb 01Option Exercise0.006,398022,107Feb 05 06:09 PM
LILLY ENDOWMENT INC10% OwnerDec 13Sale88.20200,00017,639,176123,075,804Dec 14 11:26 AM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthDec 11Sale86.4612,5001,080,750124,522Dec 13 03:01 PM
Zulueta Alfonso GSVP & President, Lilly Int'lDec 04Sale86.003,532303,75240,048Dec 05 05:35 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 04Sale86.1836,5853,152,89554,885Dec 05 05:32 PM
Zakrowski Donald AChief Accounting OfficerDec 03Option Exercise0.003,28104,167Dec 05 05:48 PM
Fry Stephen FSVP, HR & DiversityDec 03Option Exercise0.007,557086,501Dec 05 05:46 PM
Ricks David APresident & CEODec 03Option Exercise0.005,4960110,059Dec 05 05:43 PM
Zulueta Alfonso GSVP & President, Lilly Int'lNov 10Sale83.672,003167,59143,580Nov 13 12:55 PM
LILLY ENDOWMENT INC10% OwnerOct 04Sale86.81205,00017,795,025123,275,804Oct 05 02:56 PM
LILLY ENDOWMENT INC10% OwnerSep 29Sale85.14195,00016,602,601123,480,804Oct 02 03:39 PM
LILLY ENDOWMENT INC10% OwnerSep 15Sale82.53190,00015,679,772123,675,804Sep 18 03:42 PM
LILLY ENDOWMENT INC10% OwnerAug 31Sale81.06180,00014,590,080123,865,804Sep 01 01:45 PM
LILLY ENDOWMENT INC10% OwnerJul 31Sale83.09220,00018,279,478124,045,804Aug 01 10:55 AM